Locally advanced Medullary thyroid cancer

Drug	Drug Name	Drug Description
DB05294	Vandetanib	An antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Drug	Drug Name	Target	Type
DB05294	Vandetanib	Vascular endothelial growth factor A	target
DB05294	Vandetanib	Epidermal growth factor receptor	target
DB05294	Vandetanib	Multidrug resistance-associated protein 1	transporter
DB05294	Vandetanib	ATP-binding cassette sub-family G member 2	transporter
DB05294	Vandetanib	Proto-oncogene tyrosine-protein kinase receptor Ret	target
DB05294	Vandetanib	Dimethylaniline monooxygenase [N-oxide-forming] 1	enzyme
DB05294	Vandetanib	Dimethylaniline monooxygenase [N-oxide-forming] 3	enzyme
DB05294	Vandetanib	Protein-tyrosine kinase 6	target
DB05294	Vandetanib	Angiopoietin-1 receptor	target
DB05294	Vandetanib	Alpha-1-acid glycoprotein 1	carrier
DB05294	Vandetanib	Serum albumin	carrier
DB05294	Vandetanib	Cytochrome P450 3A4	enzyme
DB05294	Vandetanib	Solute carrier family 22 member 2	transporter
DB05294	Vandetanib	P-glycoprotein 1	transporter

Drug	Drug Name	Phase	Status	Count